Archer-Daniels-Midland Company

The forensic scores should be read as screening tools rather than conclusions. The Beneish M-Score is -2.949, below the -1.78 threshold, so it is not in the elevated manipulation-risk zone; that is a screening result and does not establish that the reported figures are accurate. The Altman Z-Score is 1.30, which the label places in the distress zone, a signal of financial strain rather than a forecast of default. The Piotroski F-Score is 5 of 8 computable signals, a count of the checks that could be computed from the data, not a pass or fail. The Fog Index of 18.07 falls in the very hard to read band, so the MD&A demands more effort than typical. Balance-sheet context is mixed: long-term debt fell to $6.61 billion from $7.58 billion, while equity rose to $22.74 billion from $22.18 billion. The Programs, described in Note 14 of the 10-Q, add receivables-based funding that sits alongside reported debt. The risk factors tie the cost-reduction plan to the Nutrition segment, so that segment's results are a useful place to test management's narrative against the reported figures. Readers may want to look at Note 8 on investments in affiliates and Note 16 on legal proceedings, which the filing incorporates by reference but which the excerpt does not detail. In the first half of 2026, dividends were $510 million versus $495 million, no shares were repurchased, and $115 million remained under the authorization that runs through December 31, 2029.

Catalyst.Management's stated focus, as described in the Item 1A risk factor text, is operational excellence and targeted cost reductions, including operating leverage within the Nutrition segment. Reported revenue rose 2.4% to $24.96 billion in 2025 from $24.37 billion in 2024, and operating cash flow climbed to $5.45 billion from $2.79 billion. In the first half of 2026, the 10-Q shows net repayments under short-term credit agreements of $389 million, down from $1.1 billion a year earlier, and no share repurchases. The accounts receivable securitization programs provide up to $3.0 billion of funding, with $722 million unused as of June 30, 2026.

Hidden risk.The most easily missed tension is between cash and earnings. Net income fell 40% to $1.08 billion in 2025 from $1.8 billion in 2024, so the 5.06 ratio of operating cash flow to net income reflects a much smaller profit base and should not be read as a sign of stronger earnings. Purchase obligations rose to $16.2 billion at June 30, 2026 from $13.8 billion at December 31, 2025, with $13.5 billion expected within twelve months. The Altman Z-Score of 1.30 is in the distress zone, and the MD&A Fog Index of 18.07 is in the very hard to read band. Risk factors also flag dependence on a single plant for certain products and limited control over joint ventures.